Notícias

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.

Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.

For most investors, the race to become the world’s most valuable company feels like a contest between Nvidia (NASDAQ:NVDA) and a handful of AI-first businesses. Yet a growing number of investors are starting to think the biggest AI winner may be a company emerging from industries already possessing something harder to build than a large ... Forget Nvidia and SpaceX. This 150-Year-Old Indiana Company Could Become the World’s Largest in 5 Years

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

OpenAI confidentially files IPO paperwork, Apple’s AI reveal, Wall Street likes Lilly over Novo in weight-loss wars, and more news to start your day.

Eli Lilly (LLY) shares were up early Tuesday as the drugmaker entered into a collaboration and licen

(Bloomberg) -- The Pentagon accused some of China’s biggest companies, including Alibaba Group Holding Ltd., Baidu Inc. and BYD Co. of supporting the Chinese military, doubling down on an earlier decision to label crown jewels of the country’s corporate world as threats to US national security.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’LA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump Says He, Not Congress, Is in Charge of Kennedy Center

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.1% in the afternoon session after the company reported positive Phase 3 data for retatrutide, its next-generation triple-agonist obesity drug.

Apple drew investor interest with a major AI update, Oscar Health reaffirmed its outlook, and Eli Lilly further strengthened its position in the weight-loss drug market.

The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.

By Wayne Cole SYDNEY, June 9 (Reuters) - Asian stock markets tried to stabilise on Tuesday and oil prices came off highs after Israel and Iran said they would halt attacks on each other for now, while

Infectious disease could fuel Eli Lilly's next growth phase.

Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.

Marvell’s leap into the S&P 500 caps a sharp AI-chip rebound that helped steady U.S. stocks, today, June 8, 2026.

More than a simple climb, the drugmaker's stock re-rated on a growth story that somehow keeps getting bigger.

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and

New ATTAIN trial data shows up to 30.4 lbs lost across perimenopause and post-menopause groups

New obesity drug results could strengthen Lilly's lead in weight-loss treatments.

The best long-term investment stocks are characterized by solid financial standing, consistent dividend growth and steady buybacks of their own shares.

Eli Lilly (LLY) investors have been struggling to answer a deceptively straightforward question for the last two years. How big can the obesity medicine business get? The answer has already helped produce one of the most powerful growth stories in health care. Lilly’s blockbuster drugs Mounjaro and ...

Eli Lilly emerged as the "clear winner" from the ADA meeting last weekend in New Orleans, an analyst said following the event.

Novo's CEO says semaglutide could push the company beyond obesity and diabetes into longevity and appearance-related medicine.

Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug.

ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

All three major US stock indexes were up in late-morning trading Monday, after Iran's Ministry of Fo